In spite of the large medical problem which benign prostatic hyperplasia (BPH) presents, very little is known regarding the molecular basis for this disease. By analogy to recent findings in other benign tumors, it is possible that genetic alterations are important in the development of BPH. We propose to test the hypothesis that changes in the genome are associated with BPH, and that such changes may be crucial in the pathogenesis of this disease. We will take a variety of approaches to assess genomic alterations in both human and canine BPH, focusing on both spontaneous and experimentally induced disease in the latter. The three specific questions to be addressed are as follows: 1) is the development of BPH associated with the accumulation of DNA damage in the form of altered nucleotides?; 2) do the patterns of DNA methylation change in BPH, indicating a global genomic change, predisposing to genetic instability?; and 3) can any of the genetic alterations which have been found in prostate cancer be detected in the genome of BPH cells? Of particular importance to each of these questions is how these processes are affected by aging and exposure to steroid hormones, these factors being the only known etiologic agents in this disease. These studies are of particular relevance given the recent evidence presented in this program application that 1) there may be strong similarities between the etiologic pathways for both hyperplasia and cancer int he prostate, and 2) there may be an inherited (genetic) predisposition to BPH in certain individuals. It is anticipated that the proposed studies will not only provide important insight into the molecular mechanisms responsible for BPH, but also might identify new targets for more effective therapeutic intervention in this common disease.

Project Start
1998-09-30
Project End
2000-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Chon, J K; Borkowski, A; Partin, A W et al. (1999) Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161:2002-8
Crone, J K; Burnett, A L; Chamness, S L et al. (1998) Neuronal nitric oxide synthase in the canine prostate: aging, sex steroid, and pathology correlations. J Androl 19:358-64
Jarrard, D F; Paul, R; van Bokhoven, A et al. (1997) P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin Cancer Res 3:2121-8
Barrack, E R (1997) TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31:61-70
Morton Jr, R A; Watkins, J J; Bova, G S et al. (1996) Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. J Urol 156:512-6
Epner, D E; Coffey, D S (1996) There are multiple forms of glyceraldehyde-3-phosphate dehydrogenase in prostate cancer cells and normal prostate tissue. Prostate 28:372-8
McEntee, M F; Epstein, J I; Syring, R et al. (1996) Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: comparative pathology in human and nonhuman primates. Prostate 29:51-9
Sommerfeld, H J; Meeker, A K; Piatyszek, M A et al. (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56:218-22
Burnett, A L; Saito, S; Maguire, M P et al. (1995) Localization of nitric oxide synthase in spinal nuclei innervating pelvic ganglia. J Urol 153:212-7
Chamness, S L; Ricker, D D; Crone, J K et al. (1995) The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril 63:1101-7

Showing the most recent 10 out of 23 publications